Peptide and Medication Interactions: UK Guide

Drug interactions are a critical but often overlooked consideration in the peptide space. While pharmaceutical peptides like semaglutide come with well-documented interaction profiles, research peptides are rarely studied for interactions — and many users combine them with prescription medications without professional guidance.

Interactions can occur through several mechanisms:

Pharmacokinetic interactions: One substance affects how another is absorbed, distributed, metabolised, or excreted. For example, GLP-1 agonists slow gastric emptying, which can alter the absorption rate of oral medications taken at the same time.

Pharmacodynamic interactions: Two substances have additive, synergistic, or opposing effects on the same physiological system. For example, a GH secretagogue and diabetes medication may have opposing effects on blood glucose.

Physiological interactions: A peptide changes a body system in ways that affect how another drug works. For example, peptides that alter blood clotting mechanisms may interact with anticoagulant medications.

The absence of documented interactions for a research peptide does not mean interactions do not exist — it means they have not been studied. This makes disclosure to your healthcare providers and cautious use even more important.

If you are taking any prescription medication and considering peptide use, discuss it with your prescriber or pharmacist. They can assess potential interactions and adjust your treatment plan accordingly.

GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) significantly slow gastric emptying — the rate at which food and medication leave the stomach and enter the small intestine. This is one of the mechanisms by which they reduce appetite, but it also has important implications for oral medications:

Medications potentially affected by delayed absorption:

• •Oral contraceptives: Delayed absorption may reduce peak blood levels, potentially affecting efficacy. While clinical studies with semaglutide have not shown a statistically significant reduction in contraceptive efficacy, the MHRA advises caution. Consider barrier methods during initial dose titration or switch to a non-oral contraceptive method (patch, implant, IUD).

• •Paracetamol and oral analgesics: Delayed gastric emptying slows the onset of action. The total amount absorbed may be unchanged, but peak levels are lower and time to effect is longer.

• •Oral antibiotics: Absorption timing may be altered. For time-sensitive antibiotics, discuss timing with your pharmacist.

• •Levothyroxine: Thyroid hormone replacement requires consistent absorption. GLP-1 agonists may alter levothyroxine absorption kinetics, potentially requiring dose adjustments and more frequent thyroid function monitoring.

• •Oral diabetes medications: Particularly relevant for sulfonylureas and meglitinides (see diabetes interactions section below).

Practical guidance: - Take critical medications at least 1 hour before or 2 hours after meals when possible - Monitor drug effects more closely during GLP-1 agonist initiation and dose titration - Report any unexpected changes in medication effectiveness to your prescriber - For medications with narrow therapeutic windows (e.g., warfarin, anti-epileptics), enhanced monitoring is advisable

Growth hormone secretagogues (CJC-1295, ipamorelin, GHRP-2, GHRP-6, MK-677) stimulate growth hormone release, which has significant metabolic effects — particularly on glucose regulation:

How GH affects blood sugar: Growth hormone is a counter-regulatory hormone to insulin. It promotes hepatic glucose output, reduces peripheral glucose uptake, and increases insulin resistance. This is why acromegaly (excess GH production) frequently causes diabetes.

Interactions with diabetes medications:

• •Insulin: GH secretagogues may increase insulin requirements. Blood glucose may rise, particularly fasting glucose. Patients on insulin should monitor more frequently and may need dose adjustments.

• •Metformin: Generally well-tolerated alongside GH secretagogues, as metformin primarily reduces hepatic glucose output. However, monitoring is still advisable.

• •Sulfonylureas (gliclazide, glimepiride): These stimulate insulin secretion. The opposing effects of GH (raising glucose) and sulfonylureas (lowering glucose) can create unpredictable blood sugar patterns. Enhanced monitoring is essential.

• •SGLT2 inhibitors (dapagliflozin, empagliflozin): The combination has not been studied, but the glucose-raising effects of GH may partially counteract the glucose-lowering effects of SGLT2 inhibitors.

• •GLP-1 agonists: Using a GLP-1 agonist alongside a GH secretagogue creates opposing metabolic effects — GLP-1 agonists improve insulin sensitivity while GH raises insulin resistance. The clinical significance of this interaction is not well characterised.

Key recommendation: If you have type 2 diabetes or pre-diabetes, GH secretagogues carry real metabolic risks. Discuss with your diabetologist or GP. Regular HbA1c and glucose monitoring is essential. MK-677 (ibutamoren) is particularly concerning due to its long-acting nature and documented effects on fasting glucose.

Two medication categories require particular attention when considering peptide use:

Anticoagulants and antiplatelet agents:

• •Warfarin: This vitamin K antagonist has a narrow therapeutic index (small changes in blood levels can be clinically significant). Any substance that alters gut absorption, liver metabolism, or protein binding could theoretically affect warfarin levels. GLP-1 agonists' effects on gastric emptying may alter warfarin absorption kinetics. Patients on warfarin should have INR monitored more frequently when starting or changing peptide use.

• •DOACs (rivaroxaban, apixaban, edoxaban, dabigatran): These direct oral anticoagulants may also be affected by altered gastric emptying from GLP-1 agonists. While clinical significance has not been established, caution is warranted.

• •Antiplatelet agents (aspirin, clopidogrel): GLP-1 agonist effects on absorption may alter peak levels. For clopidogrel, which requires hepatic activation, delayed absorption could theoretically affect conversion to the active metabolite.

• •BPC-157 and TB-500: These research peptides affect wound healing and tissue repair pathways. Their effects on coagulation are not well characterised. Use alongside anticoagulants or antiplatelets should be approached with extreme caution and medical supervision.

Thyroid medications:

• •Levothyroxine: As noted above, GLP-1 agonists may alter absorption. Additionally, GH secretagogues can affect thyroid function — growth hormone stimulates conversion of T4 to T3 and may suppress TSH. Patients on levothyroxine who begin GH secretagogues should have thyroid function monitored at 6–8 week intervals initially.

• •Carbimazole/propylthiouracil (for hyperthyroidism): No specific peptide interactions are documented, but any compound affecting immune function (thymosin alpha-1, thymic peptides) could theoretically influence autoimmune thyroid conditions. Medical supervision is essential.

Several additional interaction categories deserve awareness:

Immunosuppressants (tacrolimus, ciclosporin, mycophenolate): - Immune-modulating peptides such as thymosin alpha-1, LL-37, and KPV could theoretically interact with immunosuppressive medication by stimulating immune pathways that the immunosuppressant is designed to suppress - This is a serious concern for transplant recipients, where even modest immune stimulation could trigger rejection - Never use immune-modulating peptides if you are on immunosuppressive therapy without explicit specialist approval

Antihypertensives: - GLP-1 agonists have modest blood pressure-lowering effects, which could be additive with antihypertensive medications. This is generally beneficial but may require dose adjustment in some patients - GH secretagogues may transiently increase blood pressure through fluid retention

Psychiatric medications: - Selank and semax affect GABAergic, serotonergic, and dopaminergic systems. Theoretical interactions with SSRIs, SNRIs, benzodiazepines, and antipsychotics are plausible but unstudied - Combining serotonergic peptides with serotonergic medications carries a theoretical (though unquantified) risk of serotonin syndrome - Never discontinue or adjust psychiatric medications without your prescriber's guidance

Anaesthetics and surgical medications: - Always disclose all peptide use to your anaesthetist before any surgical procedure. GLP-1 agonists' effects on gastric emptying increase aspiration risk during anaesthesia. Current guidelines recommend stopping GLP-1 agonists at least one week before elective surgery requiring general anaesthesia

Supplements: - High-dose zinc may interfere with copper peptide (GHK-Cu) absorption and efficacy - Vitamin C in high doses may affect peptide stability in reconstituted solutions

The UK's Yellow Card Scheme is the system by which the MHRA monitors the safety of medicines and medical devices after they reach the market. Reporting suspected adverse reactions — including possible drug-peptide interactions — is an important contribution to public safety.

What to report: - Any suspected adverse reaction to a medicine, including unexpected effects when combining medications with peptides - Side effects from prescription GLP-1 agonists or any other pharmaceutical peptide - Adverse effects from products marketed as research peptides or supplements - Any suspected interaction between a peptide and your regular medication

How to report: - Online: Visit yellowcard.mhra.gov.uk - App: Download the Yellow Card app (iOS and Android) - Phone: Call the Yellow Card hotline on 0800 731 6789 - Post: Yellow Card forms are available from your pharmacy

Who can report: Anyone can submit a Yellow Card — patients, carers, healthcare professionals. You do not need to be certain that the product caused the reaction. Suspicion is sufficient.

Why it matters: Pre-approval clinical trials typically involve thousands of participants over 1–3 years. Rare interactions and long-term effects can only be detected through post-marketing surveillance involving millions of users over many years. Every report contributes to a safer understanding of these compounds.

Important: If you experience a serious adverse reaction (one requiring hospitalisation, causing lasting disability, or life-threatening), seek immediate medical attention first. You can submit the Yellow Card report afterwards.

*This guide is for educational purposes only and does not constitute medical or pharmaceutical advice. Always disclose all medications and supplements — including peptides — to your prescriber and pharmacist. Never adjust prescription medication without professional guidance.*